Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation Business Practice

Business-in-Brief

  • Purdue Pharma pleaded guilty to three charges concerning its role in the supply of OxyContin, bringing an end to its civil case with the US Department of Justice. The charges included two counts of conspiracy to violate the Federal Anti-Kickback Statute – a law that prevents the exchange of items or services for reward referrals – and one count of dual-object conspiracy to defraud the US.
  • Most Favoured Nation, a drug pricing policy, was set into motion in late November by President Donald Trump. The pricing model is expected to lower the cost of 50 prescription medicines in line with the prices paid by Europe’s wealthiest nations. The policy will come into effect on January 1, 2021.
  • In line with a new 15-year plan, Roche’s Genentech is expected to almost double its headquarters space to 9 million square feet. The upgraded sites will support the company’s R&D and manufacturing needs, and will accommodate an additional 12,000 members of staff.
  • A collaboration between Gavi, The Vaccine Alliance, and the International Organization for Migration pledges to provide vaccinations for those affected by emergency or humanitarian crises, and encourage companies to consider those who may otherwise be missed in their COVID-19 responses. “Children from migrant, refugee, and displaced populations are too often overlooked when it comes to basic health care. This obviously becomes all the more important as we plan to roll out COVID-19 vaccines worldwide; we cannot allow these populations to miss out on what could be one of our best routes out of this pandemic,” said Gavi’s CEO, Seth Berkley, in a statement.

Enjoy our FREE content!

Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE!

Login

Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register